A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Launched by ELI LILLY AND COMPANY · May 7, 2025
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called orforglipron to see how well it helps people with obesity or overweight who also have type 2 diabetes manage their blood sugar levels. Participants will be compared to a group receiving a placebo, which is a treatment that looks like the medication but doesn’t actually contain any active ingredients. The trial will last about 18 months, and it aims to find out if orforglipron can improve how well participants control their diabetes.
To be eligible for this study, participants need to be adults aged 65 to 74 with a body mass index (BMI) of 25 or higher, indicating they are overweight or obese. They must also have type 2 diabetes and a specific blood sugar level. People who have type 1 diabetes, unstable weight changes recently, or certain heart or liver conditions cannot participate. If you join the trial, you'll be part of an important effort to find new ways to help manage diabetes and weight, and you'll receive regular check-ups to monitor your health throughout the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have body mass index (BMI) ≥25 kilograms per square meter (kg/m2) at screening
- • Have type 2 diabetes
- • Have hemoglobin A1c (HbA1c) ≥7% and ≤10% at screening
- • Have a history of at least one unsuccessful dietary effort to lose body weight
- Exclusion Criteria:
- • Have type 1 diabetes
- • Have an unstable body weight within 90 days prior to screening
- • Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening
- • Have acute or chronic hepatitis or pancreatitis
- • Are taking other medications or alternative remedies to manage weight loss
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Buenos Aires, , Argentina
Corvallis, Oregon, United States
Woodstock, Georgia, United States
Beijing, Beijing, China
Harbin, Heilongjiang, China
Tianjin, Tianjin, China
Beijing, Beijing, China
Chengdu, Sichuan, China
Rockville, Maryland, United States
Meridian, Idaho, United States
Smithfield, Pennsylvania, United States
New Delhi, Delhi, India
Chapel Hill, North Carolina, United States
Nanjing, Jiangsu, China
Uherske Hradiste, , Czechia
Nanjing, Jiangsu, China
Philadelphia, Pennsylvania, United States
Yokohama, Kanagawa, Japan
Chuo Ku, Tokyo, Japan
Jinan, Shandong, China
Guangzhou, Guangdong, China
Houston, Texas, United States
Deland, Florida, United States
Chuo Ku, Tokyo, Japan
Bhubaneswar, Odisha, India
Oldenburg, Schleswig Holstein, Germany
San Pedro Garza Garcia, , Mexico
Hefei, Anhui, China
Essen, Nordrhein Westfalen, Germany
Mérida, , Mexico
Chongqing, Chongqing, China
Beijing, Beijing, China
Chitose, Hokkaido, Japan
Suita Shi, Osaka, Japan
Uherske Hradiste, Zlínský Kraj, Czechia
Shavano Park, Texas, United States
Pune, Maharashtra, India
Praha, Praha 4, Czechia
Essen, Nordrhein Westfalen, Germany
Leipzig, Sachsen, Germany
Chuo Ku, Tokyo, Japan
Merida, Yucatán, Mexico
Luoyang Shi, Henan, China
Missoula, Montana, United States
Shinjuku Ku, Tokyo, Japan
Yamato Shi, Kanagawa, Japan
Rosario, Santa Fe, Argentina
San Pedro Garza Garcia, Nuevo León, Mexico
Ushiku, Ibaraki, Japan
San Ramon, California, United States
Mihama Ku,Chiba City, Chiba, Japan
Santa Fe, , Argentina
Tampa, Florida, United States
Dallas, Texas, United States
Savannah, Georgia, United States
Ceske Budejovice, Jihočeský Kraj, Czechia
Leipzig, Sachsen, Germany
Guwahati, Assam, India
Hubli, Karnataka, India
Tokyo, , Japan
Tucson, Arizona, United States
Hamburg, , Germany
Tsuchiura, Ibaraki, Japan
Charlotte, North Carolina, United States
český Krumlov, , Czechia
Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
Caba, Ciudad Autónoma De Buenos Aires, Argentina
Fayetteville, North Carolina, United States
Ciudad Autónoma De Buenos Aires, Buenos Aires, Argentina
Chihuahua, , Mexico
Dorado, , Puerto Rico
Thousand Oaks, California, United States
Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
Hollywood, Florida, United States
Guaynabo, , Puerto Rico
Santa Ana, California, United States
Hyderabad, Telangana, India
Rishikesh, Uttarakhand, India
Mexico City, Distrito Federal, Mexico
Decatur, Georgia, United States
Mérida, Yucatán, Mexico
Ostrava, Moravskoslezský Kraj, Czechia
Fort Lauderdale, Florida, United States
Ocoee, Florida, United States
Decatur, Georgia, United States
New Iberia, Louisiana, United States
Silver Spring, Maryland, United States
Carson City, Nevada, United States
Las Vegas, Nevada, United States
Mission, Texas, United States
Munich, Bayern, Germany
Takamatsu, Kagawa, Japan
Mexico, Distrito Federal, Mexico
Guadalajara, Jalisco, Mexico
Decatur, Georgia, United States
Buenos Aires, , Argentina
Ceske Budejovice, , Czechia
Merida, , Mexico
Caba, , Argentina
Praha, , Czechia
Ostrava, , Czechia
Chitose, Hokkaido, Japan
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported